Immunotherapy for NSCLC

At the 23rd Annual Perspectives in Thoracic Oncology meeting, Joshua M. Bauml, MD, Assistant Professor of Medicine at the Hospital of the University of Pennsylvania, Philadelphia, told attendees about the role of immunotherapy in NSCLC.

Recent News

FDA Alerts

FDA Issues Safety Alert on Tazemetostat Following Secondary Malignancy Risk

05/13/2026

Emily Estrada

The FDA issued a safety alert regarding tazemetostat, citing an increased risk of hematologic second primary malignancies observed in the ongoing SYMPHONY-1 trial.

The FDA issued a safety alert...

05/13/2026

Oncology

FDA Approval

FDA Approves Sonrotoclax for Patients With Relapsed/Refractory Mantle Cell Lymphoma

05/13/2026

Emily Estrada

Based on results from the BGB-11417-201 trial, the FDA has approved sonrotoclax for previously treated patients with relapsed/refractory mantle cell lymphoma.

Based on results from the...

05/13/2026

Oncology

FDA Approval

FDA Approves Oral Decitabine and Cedazuridine Plus Venetoclax for Newly Diagnosed Acute Myeloid Leukemia

05/13/2026

Janelle Bradley

The FDA granted approval to the first fully oral regimen of decitabine and cedazuridine plus venetoclax for adults with newly diagnosed acute myeloid leukemia who are ineligible for intensive chemotherapy.

The FDA granted approval to the...

05/13/2026

Oncology

News

Tucatinib Plus T-DM1 Shows Sustained Disease Control in HER2-Positive Advanced Breast Cancer

05/13/2026

Emily Estrada

Final results from the phase 3 HER2CLIMB-02 trial demonstrated that tucatinib plus T-DM1 improved PFS in patients with HER2-Positive locally advanced or metastatic breast cancer, including those with brain metastases.

Final results from the phase 3...

05/13/2026

Oncology

News

Trastuzumab Deruxtecan Plus Paclitaxel, Trastuzumab, and Pertuzumab Improves Residual Cancer Burden in HER2-Positive Early Breast Cancer

05/11/2026

Stephanie Holland

Post hoc analysis results from the phase 3 DESTINY-Breast11 trial demonstrated that neoadjuvant trastuzumab deruxtecan plus paclitaxel, trastuzumab, and pertuzumab improved residual cancer burden and pathologic response in HER2-positive early...

Post hoc analysis results from...

05/11/2026

Oncology

News

Sacituzumab Govitecan Plus Trastuzumab Showed Limited Activity After T-DXd in HER2-Positive Metastatic Breast Cancer

05/11/2026

Stephanie Holland

According to results from the phase 2 SATEEN trial, sacituzumab govitecan plus trastuzumab demonstrated limited clinical activity in patients with HER2-positive metastatic breast cancer previously treated with trastuzumab deruxtecan.

According to results from the...

05/11/2026

Oncology

FDA Approval

FDA Approves Zenocutuzumab for Patients With NRG1 Fusion-Positive Advanced Cholangiocarcinoma

05/08/2026

Stephanie Holland

Based on results from the phase 2 eNRGy trial, the FDA has approved zenocutuzumab for previously treated patients with advanced cholangiocarcinoma harboring NRG1 gene fusions.

Based on results from the phase...

05/08/2026

Oncology

News

Daraxonrasib Shows Clinical Promise in Patients With RAS-mutated Pancreatic Ductal Adenocarcinoma

05/07/2026

Stephanie Holland

Results from a phase 1/2 study demonstrated that the daraxonrasib showed clinical promise in previously treated patients with RAS-mutated pancreatic ductal adenocarcinoma.

Results from a phase 1/2 study...

05/07/2026

Oncology

FDA Approval

FDA Approves Extended-Release Ruxolitinib Across Hematologic Indications

05/07/2026

Stephanie Holland

Based on pharmacokinetic bioequivalence data, the FDA has approved extended-release ruxolitinib for patients with myelofibrosis, polycythemia vera, and graft-versus-host disease.

Based on pharmacokinetic...

05/07/2026

Oncology

FDA Alerts

Camizestrant Fails to Gain Support from the FDA’s Advisory Committee in ESR1-Mutated Advanced Breast Cancer

05/07/2026

Stephanie Holland

Based on results from the SERENA-6 trial, the FDA’s Oncologic Drugs Advisory Committee has voted that camizestrant plus CDK4/6 inhibition does not demonstrate a favorable benefit-risk profile in patients with HR-positive, HER2-negative...

Based on results from the...

05/07/2026

Oncology